Gene expression profiles as biomarkers for the prediction of chemotherapy drug response in human tumour cells

Anti-Cancer Drugs

Volumn 18, Issue 5, 2007, Pages 499-523

  Parissenti, Amadeo M ^a,b,c   Hembruff, Stacey L ^a   Villeneuve, David J ^a   Veitch, Zachary ^b   Guo, Baoqing ^a   Eng, Jamei ^c  

^a SUDBURY REGIONAL HOSPITAL   (Canada)

^b LAURENTIAN UNIVERSITY   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Anticancer drugs; Drug response; Gene profiling; Microarray analysis; Pharmacogenomics; Predictive biomarkers; Quantitative reverse transcription polymerase chain reaction

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTRAMUSTINE; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; IRINOTECAN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; TAXANE DERIVATIVE; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID;

BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CARDIOTOXICITY; CELL STRAIN MCF 7; CHROMOSOME 5P; CHROMOSOME 9; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; CORRELATION ANALYSIS; DNA MICROARRAY; DNA REPAIR; DNA REPLICATION; DNA SYNTHESIS; ESOPHAGUS CANCER; GENE EXPRESSION; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; NORTHERN BLOTTING; OVARY CANCER; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR;

ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL MARKERS; CAMPTOTHECIN; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; GENE EXPRESSION PROFILING; HUMANS; NUCLEOSIDES; PREDICTIVE VALUE OF TESTS; TAXOIDS; VINCA ALKALOIDS;

EID: 34247138423     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3280262427     Document Type: Review

References (196)

1. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98:10869-10874.
2. Kohlmann A, Schoch C, Schnittger S, Dugas M, Hiddemann W, Kern W, et al. Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients. Leukemia 2004; 18:63-71.
3. van't Veer LJ, Dai H, Van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-536.
4. van de Vijver MJ, He YD, Van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999-2009.
5. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003; 63:1602-1607.
6. Gordon GJ, Jensen RV, Hsiao LL, Gullans SR, Blumenstock JE, Richards WG, et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 2003; 95:598-605.
7. Nevins JR, Huang ES, Dressman H, Pittman J, Huang AT, West M. Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction. Hum Mol Genet 2003; 12:153-157.
8. Yu K, Lee CH, Tan PH, Hong GS, Wee SB, Wong CY, et al. A molecular signature of the Nottingham prognostic index in breast cancer. Cancer Res 2004; 64:2962-2968.
9. Watters JW, McLeod HL. Cancer pharmacogenomics: current and future applications. Biochim Biophys Acta 2003; 1603:99-111.
10. Petros WP, Evans WE. Pharmacogenomics in cancer therapy: is host genome variability important? Trends Pharmacol Sci 2004; 25:457-464.
11. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006; 6:117-129.
12. Beck WT, Danks MK. Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Semin Cancer Biol 1991; 2:235-244.
13. Rabbani A, Finn RM, Ausio J. The anthracycline antibiotics: antitumor drugs that alter chromatin structure. Bioessays 2005; 27:50-56.
14. Richardson DS, Johnson SA. Anthracyclines in haematology: preclinical studies, toxicity and delivery systems. Blood Rev 1997; 11:201-223.
15. Zijlstra JG, De Jong S, De Vries EG, Mulder NH. Topoisomerases, new targets in cancer chemotherapy. Med Oncol Tumor Pharmacother 1990; 7:11-18.
16. Tarr M, Van Helden PD. Inhibition of transcription by adriamycin is a consequence of the loss of negative superhelicity in DNA mediated by topoisomerase II. Mol Cell Biochem 1990; 93:141-146.
17. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57:727-741.
18. Binaschi M, Bigioni M, Cipollone A, Rossi C, Goso C, Maggi CA, et al. Anthracyclines: selected new developments. Curr Med Chem Anticancer Agents 2001; 1:113-130.
19. Ormrod D, Holm K, Goa K, Spencer C. Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer. Drugs Aging 1999; 15:389-416.
20. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455:152-162.
21. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258:1650-1654.
22. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, et al. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 1991; 51:6592-6595.
23. Giaccone G, Gazdar AF, Beck H, Zunino F, Capranico G. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 1992; 52:1666-1674.
24. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug- resistant human breast cancer cells. J Biol Chem 1986; 261:15544-15549.
25. Batist G, Behrens BC, Makuch R, Hamilton TC, Katki AG, Louie KG, et al. Serial determinations of glutathione levels and glutathione-related enzyme activities in human tumor cells in vitro. Biochem Pharmacol 1986; 35:2257-2259.
26. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2:811-814.
27. Cai Z, Stancou R, Korner M, Chouaib S. Impairment of Fas-antigen expression in adriamycin-resistant but not TNF-resistant MCF7 tumor cells. Int J Cancer 1996; 68:535-546.
28. Seymour L, Bezwoda WR, Dansey RD. P-glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer. Breast Cancer Res Treat 1995; 36:61-69.
29. Linn SC, Pinedo HM, van Ark-Otte J, van d V, Hoekman K, Honkoop AH, et al. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 1997; 71:787-795.
30. Broxterman HJ, Sonneveld P, van Putten WJ, Lankelma J, Eekman CA, Ossenkoppele GJ, et al. P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy. Leukemia 2000; 14:1018-1024.
31. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001; 61:2505-2512.
32. Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 2000; 6:2751-2758.
33. Colleoni M, Orvieto E, Nole F, Orlando L, Minchella I, Viale G, et al. Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer 1999; 35:574-579.
34. Jukkola A, Bloigu R, Soini Y, Savolainen ER, Holli K, Blanco G. c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur J Cancer 2001; 37:347-354.
35. Egawa C, Motomura K, Miyoshi Y, Takamura Y, Taguchi T, Tamaki Y, et al. Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers. Breast Cancer Res Treat 2003; 78:45-50.
36. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000; 275:23899-23903.
37. Welcsh PL, Owens KN, King MC. Insights into the functions of BRCA1 and BRCA2. Trends Genet 2000; 16:69-74.
38. Choi DH, Lee MH, Bale AE, Carter D, Haffty BG. Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol 2004; 22:1638-1645.
39. Montagna M, Santacatterina M, Corneo B, Menin C, Serova O, Lenoir GM, et al. Identification of seven new BRCA1 germline mutations in Italian breast and breast/ovarian cancer families. Cancer Res 1996; 56:5466-5469.
40. Carter A, Dann EJ, Katz T, Shechter Y, Oliven A, Regev R, et al. Cells from chronic myelogenous leukaemia patients at presentation exhibit multidrug resistance not mediated by either MDR1 or MRP1. Br J Haematol 2001; 114:581-590.
41. Chintamani , Singh JP, Mittal MK, Saxena S, Bansal A, Bhatia A, et al. Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer - a prospective clinical study. World J Surg Oncol 2005; 3:61.
42. Konishi I, Nanbu K, Mandai M, Tsuruta Y, Kataoka N, Nagata Y, et al. Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-pi in the tumor cells of cervical carcinoma. Gynecol Oncol 1998; 70:365-371.
43. van der Holt B, Lowenberg B, Burnett AK, Knauf WU, Shepherd J, Piccaluga PP, et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 2005; 106:2646-2654.
44. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, et al. Phase II study of tariquidar, a selective p-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 2005; 104:682-691.
45. Zwelling LA, Bales E, Altschuler E, Mayes J. Circumvention of resistance by doxorubicin, but not by idarubicin, in a human leukemia cell line containing an intercalator-resistant form of topoisomerase II: evidence for a non-topoisomerase II-mediated mechanism of doxorubicin cytotoxicity. Biochem Pharmacol 1993; 45:516-520.
46. DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M, et al. Interleukin-6 -174G-C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 2003; 63:8051-8056.
47. Liem AA, Appleyard MV, O'Neill MA, Hupp TR, Chamberlain MP, Thompson AM. Doxorubicin and vinorelbine act independently via p53 expression and p38 activation respectively in breast cancer cell lines. Br J Cancer 2003; 88:1281-1284.
48. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Safety 2000; 22:263-302.
49. Kudoh K, Ramanna M, Ravatn R, Elkahloun AG, Bittner ML, Meltzer PS, et al. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res 2000; 60:4161-4166.
50. Villeneuve DJ, Hembruff SL, Veitch Z, Cecchetto M, Dew WA, Parissenti AM. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Breast Cancer Res Treat 2006; 96:17-39.
51. Villeneuve DJ, Parissenti AM. The use of DNA microarrays to investigate the pharmacogenomics of drug response in living systems. Curr Top Med Chem 2004; 4:1329-1345.
52. Hembruff SL, Villeneuve DJ, Parissenti AM. The optimization of quantitative reverse transcription PCR for verification of cDNA microarray data. Anal Biochem 2005; 345:237-249.
53. Watts GS, Futscher BW, Isett R, Gleason-Guzman M, Kunkel MW, Salmon SE. cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways. J Pharmacol Exp Ther 2001; 299:434-441.
54. Kang HC, Kim IJ, Park JH, Shin Y, Ku JL, Jung MS, et al. Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 2004; 10:272-284.
55. Mirkin BL, Clark S, Zheng X, Chu F, White BD, Greene M, et al. Identification of midkine as a mediator for intercellular transfer of drug resistance. Oncogene 2005; 24:4965-4974.
56. Chang BD, Swift ME, Shen M, Fang J, Broude EV, Roninson IB. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc Natl Acad Sci U S A 2002; 99:389-394.
57. Moriyama M, Hoshida Y, Otsuka M, Nishimura S, Kato N, Goto T, et al. Relevance network between chemosensitivity and transcriptome in human hepatoma cells. Mol Cancer Ther 2003; 2:199-205.
58. Bonilla E, del MJ. Deregulation of gene expression in fetal oocytes exposed to doxorubicin. Biochem Pharmacol 2003; 65:1701-1707.
59. Niiya M, Niiya K, Kiguchi T, Shibakura M, Asaumi N, Shinagawa K, et al. Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells. Cancer Chemother Pharmacol 2003; 52:391-398.
60. Troester MA, Hoadley KA, Parker JS, Perou CM. Prediction of toxicantspecific gene expression signatures after chemotherapeutic treatment of breast cell lines. Environ Health Perspect 2004; 112:1607-1613.
61. Mallory JC, Crudden G, Oliva A, Saunders C, Stromberg A, Craven RJ. A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells. Mol Pharmacol 2005; 68:1747-1756.
62. Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Dexter T, Powles T, et al. Gene expression patterns for doxorubicin (adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat 2006; 95:229-233.
63. Györffy B, Serra V, Jurchott K, Abdul-Ghani R, Garber M, Stein U, et al. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene 2005; 24:7542-7551.
64. Chazard M, Pellae-Cosset B, Garet F, Soares JA, Lucidi B, Lavail Y, et al. Taxol (paclitaxel), first molecule of a new class of cytotoxic agents: taxanes. Bull Cancer 1994; 81:173-181.
65. Distefano M, Scambia G, Ferlini C, Gaggini C, De Vincenzo R, Riva A, et al. Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance- positive human cancer cells. Int J Cancer 1997; 72:844-850.
66. Moos PJ, Fitzpatrick FA. Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci U S A 1998; 95:3896-3901.
67. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993; 15:55-61.
68. 2/M arrest and apoptosis. Nat Med 1996; 2:72-79.
69. Clark A, West K, Streicher S, Dennis P. Constitutive and inducible Akt activity promotes rsistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002; 1:707-717.
70. Anand S, Penrhyn-Lowe S, Venkitaraman A. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to taxol. Cancer Cell 2003; 3:51-62.
71. Ferlini C, Raspaglio G, Mozzetti S, Distefano M, Filippetti F, Martinelli Ferrandina G, et al. Bcl-2 down-regulatin is a novel mechanism of paclitaxel resistance. Mol Pharmacol 2003; 64:51-58.
72. Cabral F, Abraham I, Gottesman MM. Isolation of a taxol-resistant Chinese hamster ovary cell mutant that has an alteration in alpha-tubulin. Proc Natl Acad Sci U S A 1981; 78:4388-4391.
73. Schibler MJ, Huang B. The colR4 and colR15 beta-tubulin mutations in Chlamydomonas reinhardtii confer altered sensitivities to microtubule inhibitors and herbicides by enhancing microtubule stability. J Cell Biol 1991; 113:605-614.
74. Duan Z, Lamendola DE, Duan Y, Yusuf RZ, Seiden MV. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. Cancer Chemother Pharmacol 2005; 55:277-285.
75. Yoo GH, Piechocki MP, Ensley JF, Nguyen T, Oliver J, Meng H, et al. Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. Clin Cancer Res 2002; 8:3910-3921.
76. Li Y, Li X, Hussain M, Sarkar FH. Regulation of microtubule, apoptosis, and cell cycle-related genes by taxotere in prostate cancer cells analyzed by microarray. Neoplasia 2004; 6:158-167.
77. Li Y, Hussain M, Sarkar SH, Eliason J, Li R, Sarkar FH. Gene expression profiling revealed novel mechanism of action of taxotere and furtulon in prostate cancer cells. BMC Cancer 2005; 5:7.
78. Li Y, Hong X, Hussain M, Sarkar SH, Li R, Sarkar FH. Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells. Mol Cancer Ther 2005; 4:389-398.
79. Guo B, Villeneuve DJ, Hembruff SL, Kirwan AF, Blais DE, Bonin M, et al. Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure. Breast Cancer Res Treat 2004; 85:31-51.
80. McDonald SL, Stevenson DA, Moir SE, Hutcheon AW, Haites NE, Heys SD, et al. Genomic changes identified by comparative genomic hybridisation in docetaxel-resistant breast cancer cell lines. Eur J Cancer 2005; 41:1086-1094.
81. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362:362-369.
82. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005; 23:1169-1177.
83. Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005; 23:422-431.
84. Bani MR, Nicoletti MI, Alkharouf NW, Ghilardi C, Petersen D, Erba E, et al. Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Mol Cancer Ther 2004; 3:111-121.
85. Arioka H, Saijo N. Microtubules and antineoplastic drugs. Gan To Kagaku Ryoho 1994; 21:583-590.
86. Rincon M, Broadwater G, Harris L, Crocker A, Weaver D, Dressler L, et al. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Res Treat 2006; 100:301-308.
87. Gan Y, Wientjes MG, Au JL. Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res 2006; 23:1324-1331.
88. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 2006; 12:854-859.
89. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, et al. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 1990; 8:1907-1912.
90. Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K. A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma. Cancer 1998; 82:2166-2172.
91. Chitapanarux I, Tonusin A, Sukthomya V, Charuchinda C, Pukanhapan N, Lorvidhaya V. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer. Gynecol Oncol 2003; 89:402-407.
92. Aoki Y, Kurata H, Watanabe M, Fujita K, Tanaka K. Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer. Am J Clin Oncol 2004; 27:461-464.
93. Altinbas M, Er O, Ozkan M, Solak Y, Coskun HS, Kucuk C, et al. Irinotecan plus cisplatin combination against metastatic gastric cancer: phase II study. Med Oncol 2005; 22:153-160.
94. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 1994; 12:553-559.
95. Larsen AK, Gobert C. DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde? Pathol Oncol Res 1999; 5:171-178.
96. Lock RB, Ross WE. DNA topoisomerases in cancer therapy. Anticancer Drug Des 1987; 2:151-164.
97. D'Arpa P, Liu LF. Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 1989; 989:163-177.
98. Kiechle FL, Zhang X. Apoptosis: biochemical aspects and clinical implications. Clin Chim Acta 2002; 326:27-45.
99. Morris EJ, Geller HM. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity. J Cell Biol 1996; 134:757-770.
100. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 1972; 56:515-521.
101. Desai SD, Li TK, Rodriguez-Bauman A, Rubin EH, Liu LF. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res 2001; 61:5926-5932.
102. Morandi E, Zingaretti C, Chiozzotto D, Severini C, Semeria A, Horn W, et al. A cDNA-microarray analysis of camptothecin resistance in glioblastoma cell lines. Cancer Lett 2006; 231:74-86.
103. Fedier A, Schwarz VA, Walt H, Carpini RD, Haller U, Fink D. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int J Cancer 2001; 93:571-576.
104. Annereau JP, Szakacs G, Tucker CJ, Arciello A, Cardarelli C, Collins J, et al. Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol 2004; 66:1397-1405.
105. Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004; 6:129-137.
106. Maliepaard M, Van Gastelen MA, De Jong LA, Pluim D, Van Waardenburg RC, Ruevekamp-Helmers MC, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999; 59:4559-4563.
107. Maliepaard M, Van Gastelen MA, Tohgo A, Hausheer FH, Van Waardenburg RC, De Jong LA, et al. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 2001; 7:935-941.
108. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001; 11:1156-1166.
109. Carson JP, Zhang N, Frampton GM, Gerry NP, Lenburg ME, Christman MF. Pharmacogenomic identification of targets for adjuvant therapy with the topoisomerase poison camptothecin. Cancer Res 2004; 64:2096-2104.
110. Mariadason JM, Arango D, Shi Q, Wilson AJ, Corner GA, Nicholas C, et al. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 2003; 63:8791-8812.
111. Zhou Y, Gwadry FG, Reinhold WC, Miller LD, Smith LH, Scherf U, et al. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res 2002; 62:1688-1695.
112. Reinhold WC, Kouros-Mehr H, Kohn KW, Maunakea AK, Lababidi S, Roschke A, et al. Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res 2003; 63:1000-1011.
113. Urasaki Y, Laco GS, Pourquier P, Takebayashi Y, Kohlhagen G, Gioffre C, et al. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res 2001; 61:1964-1969.
114. Wu MH, Yan B, Humerickhouse R, Dolan ME. Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells. Clin Cancer Res 2002; 8:2696-2700.
115. Charasson V, Bellott R, Meynard D, Longy M, Gorry P, Robert J. Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin Pharmacol Ther 2004; 76:528-535.
116. Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, et al. Cancer cell adaptation to chemotherapy. BMC Cancer 2005; 5:78.
117. Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, Carey PD, et al. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 2004; 10:2158-2167.
118. Tian Q, Zhang J, Tan TM, Chan E, Duan W, Chan SY, et al. Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm Res 2005; 22:1837-1853.
119. Minderman H, Conroy JM, O'Loughlin KL, McQuaid D, Quinn P, Li S, et al. In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther 2005; 4:885-900.
120. Inoue Y, Shirane M, Miki C, Hiro J, Tanaka K, Kobayashi M, et al. Gene expression profiles of colorectal carcinoma in response to neo-adjuvant chemotherapy. Int J Oncol 2004; 25:1641-1649.
121. Souza V, Dong YB, Zhou HS, Zacharias W, McMasters KM. SW-620 cells treated with topoisomerase I inhibitor SN-38: gene expression profiling. J Transl Med 2005; 3:44.
122. Yu J, Shannon WD, Watson MA, McLeod HL. Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res 2005; 11:2053-2062.
123. Izzo JG, Malhotra U, Wu TT, Ensor J, Luthra R, Lee JH, et al. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 2006; 24:748-754.
124. Jia P, Wu S, Li F, Xu Q, Wu M, Chen G, et al. Breast cancer resistance protein-mediated topotecan resistance in ovarian cancer cells. Int J Gynecol Cancer 2005; 15:1042-1048.
125. Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, et al. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 2004; 24:7612-7621.
126. Oggionni M, Pilotti S, Suardi S, Ditto A, Luoni C, Mariani L, et al. p53 Gene status and response to topotecan-containing chemotherapy in advanced ovarian carcinoma. Oncology 2005; 69:154-158.
127. Daoud SS, Munson PJ, Reinhold W, Young L, Prabhu VV, Yu Q, et al. Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. Cancer Res 2003; 63:2782-2793.
128. Liu LF, Rowe TC, Yang L, Tewey KM, Chen GL. Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem 1983; 258:15365-15370.
129. Zechiedrich EL, Christiansen K, Andersen AH, Westergaard O, Osheroff N. Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate. Biochemistry 1989; 28:6229-6236.
130. Osheroff N. Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochemistry 1989; 28:6157-6160.
131. Bjorling-Poulsen M, Issinger OG. cDNA array analysis of alterations in gene expression in the promyelocytic leukemia cell line, HL-60, after apoptosis induction with etoposide. Apoptosis 2003; 8:377-388.
132. Yang XH, Sladek TL, Liu X, Butler BR, Froelich CJ, Thor AD. Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res 2001; 61:348-354.
133. L and Bax by tumor microenvironmental factors. J Natl Cancer Inst 2000; 92:18-23.
134. Chikamori K, Grabowski DR, Kinter M, Willard BB, Yadav S, Aebersold RH, et al. Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity. J Biol Chem 2003; 278:12696-12702.
135. Tao W, Hangoc G, Hawes JW, Si Y, Cooper S, Broxmeyer HE. Profiling of differentially expressed apoptosis-related genes by cDNA arrays in human cord blood CD34+ cells treated with etoposide. Exp Hematol 2003; 31:251-260.
136. Györffy B, Surowiak P, Kiesslich O, Denkert C, Schafer R, Dietel M, et al. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 2006; 118:1699-1712.
137. Györffy B, Serra V, Materna V, Schafer R, Dietel M, Schadendorf D, et al. Analysis of gene expression profiles in melanoma cells with acquired resistance against antineoplastic drugs. Melanoma Res 2006; 16:147-155.
138. O'Brien M, Kruh GD, Tew KD. The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance. J Pharmacol Exp Ther 2000; 294:480-487.
139. Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 2001; 7:1798-1804.
140. Matsumoto Y, Takano H, Kunishio K, Nagao S, Fojo T. Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells. Jpn J Cancer Res 2001; 92:778-784.
141. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 2002; 3:415-424.
142. Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 1990; 48:381-395.
143. Ghoshal K, Jacob ST. An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem Pharmacol 1997; 53:1569-1575.
144. Hu YC, Komorowski RA, Graewin S, Hostetter G, Kallioniemi OP, Pitt HA, et al. Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer. Clin Cancer Res 2003; 9:4165-4171.
145. Mild G, Bachmann F, Boulay JL, Glatz K, Laffer U, Lowy A, et al. DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer. Int J Cancer 2002; 102:254-257.
146. Etienne MC, Formento JL, Chazal M, Francoual M, Magne N, Formento P, et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 2004; 14:785-792.
147. Hasegawa T, Kim HS, Fukushima M, Wataya Y. Sequence analysis of the 50-flanking regions of human dihydropyrimidine dehydrogenase gene: identification of a new polymorphism related with effects of 5-fluorouracil. Nucleosides Nucleotides Nucleic Acids 2005; 24:233-242.
148. Wang W, Cassidy J, O'Brien V, Ryan KM, Collie-Duguid E. Mechanistic and predictive profiling of 5-Fluorouracil resistance in human cancer cells. Cancer Res 2004; 64:8167-8176.
149. Maxwell PJ, Longley DB, Latif T, Boyer J, Allen W, Lynch M, et al. Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res 2003; 63:4602-4606.
150. Park JS, Young YS, Kim JM, Yeom YI, Kim YS, Kim NS. Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. Cancer Lett 2004; 214:19-33.
151. Mackey JR, Galmarini CM, Graham KA, Joy AA, Delmer A, Dabbagh L, et al. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations. Blood 2005; 105:767-774.
152. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002; 41:93-103.
153. Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Arthur DC, et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 2004; 104:1428-1434.
154. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84:3148-3157.
155. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85:1580-1589.
156. Csapo Z, Keszler G, Safrany G, Spasokoukotskaja T, Talianidis I, Staub M, et al. Activation of deoxycytidine kinase by gamma-irradiation and inactivation by hyperosmotic shock in human lymphocytes. Biochem Pharmacol 2003; 65:2031-2039.
157. Molina-Arcas M, Bellosillo B, Casado FJ, Montserrat E, Gil J, Colomer D,
158. Gottardi D, De Leo AM, Alfarano A, Stacchini A, Circosta P, Gregoretti MG, et al. Fludarabine ability to down-regulate Bcl-2 gene product in CD5+ leukaemic B cells: in vitro/in vivo correlations. Br J Haematol 1997; 99:147-157.
159. Bignold LP. Alkylating agents and DNA polymerases. Anticancer Res 2006; 26:1327-1336.
160. Germanas J, Pandya AG. Alkylating agents. Dermatol Ther 2002; 15:317-324.
161. Chen CS, Lin JT, Goss KA, He YA, Halpert JR, Waxman DJ. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol Pharmacol 2004; 65:1278-1285.
162. Tsukamoto N, Chen J, Yoshida A. Enhanced expressions of glucose-6-phosphate dehydrogenase and cytosolic aldehyde dehydrogenase and elevation of reduced glutathione level in cyclophosphamide-resistant human leukemia cells. Blood Cells Mol Dis 1998; 24:231-238.
163. Giorgianni F, Bridson PK, Sorrentino BP, Pohl J, Blakley RL. Inactivation of aldophosphamide by human aldehyde dehydrogenase isozyme 3. Biochem Pharmacol 2000; 60:325-338.
164. Xie H, Afsharian P, Terelius Y, Mirghani RA, Yasar U, Hagbjork AL, et al. Cyclophosphamide induces mRNA, protein and enzyme activity of cytochrome P450 in rat. Xenobiotica 2005; 35:239-251.
165. Martin H, Sarsat JP, de Waziers I, Housset C, Balladur P, Beaune P, et al. Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices. Pharm Res 2003; 20:557-568.
166. Xie HJ, Lundgren S, Broberg U, Finnstrom N, Rane A, Hassan M. Effect of cyclophosphamide on gene expression of cytochromes p450 and beta-actin in the HL-60 cell line. Eur J Pharmacol 2002; 449:197-205.
167. Chen G, Waxman DJ. Identification of glutathione S-transferase as a determinant of 4-hydroperoxycyclophosphamide resistance in human breast cancer cells. Biochem Pharmacol 1995; 49:1691-1701.
168. Vester U, Kranz B, Zimmermann S, Buscher R, Hoyer PF. The response to cyclophosphamide in steroid-sensitive nephrotic syndrome is influenced by polymorphic expression of glutathion-S-transferases-M1 and -P1. Pediatr Nephrol 2005; 20:478-481.
169. Muggia FM, Fojo T. Platinums: extending their therapeutic spectrum. J Chemother 2004; 16:77-82.
170. Torigoe T, Izumi H, Ishiguchi H, Yoshida Y, Tanabe M, Yoshida T, et al. Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 2005; 5:15-27.
171. Huerta S, Harris DM, Jazirehi A, Bonavida B, Elashoff D, Livingston EH, et al. Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int J Oncol 2003; 22:663-670.
172. Kim HK, Choi IJ, Kim HS, Kim JH, Kim E, Park IS, et al. DNA microarray analysis of the correlation between gene expression patterns and acquired resistance to 5-FU/cisplatin in gastric cancer. Biochem Biophys Res Commun 2004; 316:781-789.
173. Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, Reed E. Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem 1998; 273:23419-23425.
174. Higashiyama M, Miyoshi Y, Kodama K, Yokouchi H, Takami K, Nishijima M, et al. p53-regulated GML gene expression in non-small cell lung cancer. a promising relationship to cisplatin chemosensitivity. Eur J Cancer 2000; 36:489-495.
175. Lin CS, Aebersold RH, Kent SB, Varma M, Leavitt J. Molecular cloning and characterization of plastin, a human leukocyte protein expressed in transformed human fibroblasts. Mol Cell Biol 1988; 8:4659-4668.
176. Arpin M, Friederich E, Algrain M, Vernel F, Louvard D. Functional differences between L- and T-plastin isoforms. J Cell Biol 1994; 127:1995-2008.
177. Hisano T, Ono M, Nakayama M, Naito S, Kuwano M, Wada M. Increased expression of T-plastin gene in cisplatin-resistant human cancer cells: identification by mRNA differential display. FEBS Lett 1996; 397:101-107.
178. Murakami T, Shibuya I, Ise T, Chen ZS, Akiyama S, Nakagawa M, et al. Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance. Int J Cancer 2001; 93:869-874.
179. Qin LF, Lee TK, Ng IO. Gene expression profiling by cDNA array in human hepatoma cell line in response to cisplatin treatment. Life Sci 2002; 70:1677-1690.
180. Macleod K, Mullen P, Sewell J, Rabiasz G, Lawrie S, Miller E, et al. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res 2005; 65:6789-6800.
181. Kruczynski A, Hill BT. Vinflunine, the latest vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol 2001; 40:159-173.
182. Duflos A, Kruczynski A, Barret JM. Novel aspects of natural and modified vinca alkaloids. Curr Med Chem Anticancer Agents 2002; 2:55-70.
183. Okouneva T, Hill BT, Wilson L, Jordan MA. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther 2003; 2:427-436.
184. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002; 2:1-17.
185. Zhou XJ, Rahmani R. Preclinical and clinical pharmacology of vinca alkaloids. Drugs 1992; 44:1-16.
186. Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005; 11:2625-2636.
187. Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of rituximab. Anticancer Drugs 2002; 13:3-10.
188. Ngan VK, Bellman K, Hill BT, Wilson L, Jordan MA. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol 2001; 60:225-232.
189. Leveque D, Jehl F. Clinical pharmacokinetics of vinorelbine. Clin Pharmacokinet 1996; 31:184-197.
190. Sorensen JB, Hansen HH. Is there a role for vindesine in the treatment of non-small cell lung cancer? Invest New Drugs 1993; 11:103-133.
191. Fan M, Goodwin ME, Birrer MJ, Chambers TC. The c-Jun NH2-terminal protein kinase/AP-1 pathway is required for efficient apoptosis induced by vinblastine. Cancer Res 2001; 61:4450-4458.
192. Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, Ueyama Y, et al. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 2002; 62:518-527.
193. Nakatsu N, Yoshida Y, Yamazaki K, Nakamura T, Dan S, Fukui Y, et al. Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays. Mol Cancer Ther 2005; 4:399-412.
194. Plasschaert SL, Groninger E, Boezen M, Kema I, de Vries EG, Uges D, et al. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Ther 2004; 76:220-229.
195. Liu D, O'Day SJ, Yang D, Boasberg P, Milford R, Kristedja T, et al. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Clin Cancer Res 2005; 11:1237-1246.
196. Lecomte T, Ferraz JM, Zinzindohoue F, Loriot MA, Tregouet DA, Landi B, et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004; 10:5880-5888.